In an era of escalating biological threats, from weaponized pathogens to evolving viruses like Mpox, small U.S. biotechs are stepping up to bolster military readiness and national security.

Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely due ...

Some genetic mutations that are expected to completely stop a gene from working surprisingly cause only mild or even no symptoms. Researchers in previous studies have discovered one reason why: cells ...

The move signals an escalation in the agency’s efforts to interfere with established procedures for testing and approving vaccines.

Moderna Inc (NASDAQ:MRNA) has delivered a 37% gain year-to-date, dramatically outpacing the biotech sector’s 0.4% YTD return.

As the U.S. backpedals on its mRNA investment, Mexico is embracing the technology through a new manufacturing pact with ...

Australia has begun a pioneering clinical trial using personalized mRNA vaccines to treat children and adolescents with ...

Despite Sanofi CEO Paul Hudson’s confidence in vaccines, the French pharma has cut at least one mRNA flu shot program. Even as CEO Paul Hudson expressed confidence in Sanofi’s vaccine business, the ...

Two and a half years after Sanofi unveiled to investors a revamped strategy to create an mRNA seasonal flu vaccine, Fierce Biotech has learned that the French pharma has put this pipeline on ice. The ...

Michael Eisenstein is a freelance writer based in Philadelphia, Pennsylvania. Every day, around two dozen people die awaiting an organ transplant in the 46 countries of the Council of Europe, together ...